FIT Biotech Overview
- Founded
- 1995
- Status
- Private
- Employees
- 11
- Latest Deal Type
- IPO
- Latest Deal Amount
- $20.2M
FIT Biotech General Information
Description
FIT Biotech Oy is a clinical-stage biotechnology company. It is primarily focused on developing antibody therapies for cancer immunotherapy as well as Deoxyribonucleic acid (DNA) vaccines for the prevention of infectious diseases such as Human immunodeficiency virus (HIV). The firm's GTU technology enables the production of antibodies in the human body instead of using industrially manufactured antibodies. The GTU technology platform has various application areas. The group generates revenue through the sales of services related to the HIV vaccine. The organization is based in Finland.
Contact Information
Website
www.fitbiotech.com
Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Delivery
Primary Office
- Biokatu 8
- 33520 Tampere
- Finland
+358 03 00000000
FIT Biotech Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. IPO | 01-Jul-2015 | $20.2M | 000.00 | 000.00 | Completed | Generating Revenue |
| 1. Early Stage VC | 29-Jun-2006 | 00.000 | 00.000 | Completed | Product Development |
FIT Biotech Patents
FIT Biotech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20110171255-A1 | Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant | Granted | 23-May-2008 | 000000000 | 0 |
| US-9474800-B2 | Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant | Active | 23-May-2008 | 000000000 | 0 |
| AU-2009248735-A1 | Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant | Granted | 23-May-2008 | 000000000 | |
| CA-2724570-A1 | Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant | Abandoned | 23-May-2008 | 000000000 | |
| AU-2009248735-B2 | Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant | Ceased | 23-May-2008 | A61K39/39 |
FIT Biotech Executive Team (3)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Erkki Pekkarinen | Chief Executive Officer | ||
| James Kuo MD | Chief Executive Officer |
FIT Biotech Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialFIT Biotech Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000000 | 23-Jan-2003 | 0000000000 | Other Devices and Supplies | 000000 00 |